Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical

There's a new surgical robot coming soon. Is the market big enough for da Vinci and a big competitor's rival system?

Is Medtronic About to Give Intuitive Surgical a Run for Its Money?

The press release published today at 11:00 a.m. EDT contained the incorrect presentation time. The correct version is below.

Correction: Medtronic EVP & CFO Karen L. Parkhill to Speak at Morgan Stanley Global Healthcare Conference

DUBLIN, Sept.  03, 2019  (GLOBE NEWSWIRE) --  Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10, 2019, in New York City.

Medtronic EVP & CFO Karen L. Parkhill to Speak at Morgan Stanley Global Healthcare Conference

This is indeed a top story as during Omar's tenure, annual revenues of Medtronic (MDT) skyrocket to double-digit growth among a slew of enormous feats that he attains.

Medtronic Names Next CEO as Omar Ishrak to Step Down in 2020

DUBLIN, Aug.  29, 2019  (GLOBE NEWSWIRE) --  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the 14th Annual Wells Fargo Securities Healthcare Conference on Thursday, September 5, 2019, in Boston.

Medtronic EVP & CVG President Mike Coyle to Speak at Wells Fargo Securities Healthcare Conference

Darden Restaurants

Microsoft

Teradyne

Target

Given the collapse in yields and market uncertainty, the appeal for dividend ETFs has been on rise on investors' drive for juicy yields and consistent income.

5 Dividend Growth Stocks on Sale

Medtronic Plc MDT, +0.61% said Wednesday its Chief Executive Omar Ishrak is planning to retire at the end of the current fiscal year on April 26, 2020.

Medtronic names Geoff Martha as next CEO, replacing Omar Ishrak who is retiring

Omar Ishrak Will Retire as CEO at End of Fiscal Year;   Remains Chairman of the Board and Becomes Executive Chairman of Medtronic 

Medtronic Announces Planned Leadership Succession

Atkore International Group

OUTFRONT Media

Symantec Corp

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 Solid Stocks Near 52-Week High With More Room to Run

Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.

Medtronic (MDT) Benefits from Strength Across Business Groups

Is  (MDT) Outperforming Other Medical Stocks This Year?

Is Medtronic (MDT) Stock Outpacing Its Medical Peers This Year?

Zimmer Biomet Hlds

ZBH vs. MDT: Which Stock Is the Better Value Option?

ZBH vs. MDT: Which Stock Should Value Investors Buy Now?

DUBLIN, Aug.  23, 2019  (GLOBE NEWSWIRE) -- The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2020 second quarter cash dividend of $0.54 per ordinary share, representing an 8 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2019. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 42 consecutive years. The dividend is payable on October 18, 2019, to shareholders of record at the close of business on September 27, 2019.

Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2020

Medtronic’s (NYSE:MDT) share price has grown around 20% over the last two years. This can be attributed to steady growth in its revenues, margin expansion, price to earnings multiple growth, and lower share count.

Why Did Medtronic's Stock Grow 20% Over The Last 2 Years?

Large-cap medtech company Medtronic PLC (NYSE: MDT) reported strong first-quarter results Tuesday, sending its shares to a 52-week high.

Medtronic Analysts Applaud Q1 Beat-And-Raise

With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.

FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk

The medical device maker's diabetes group showed strong growth, as did its restorative and minimally invasion therapies group.

Medtronic Stock Pops to New High on Earnings Beat

Medtronic, Inc. (MDT) CEO Omar Ishrak on Q1 2020 Results - Earnings Call Transcript

Home Depot

Kohl's

It was a good day for Home Depot shareholders as the home improvement retailer's stock rose more than 4% on stronger-than-expected earnings.

Earnings wrap: Home Depot and Medtronic jump on earnings, Kohl's takes a hit

The medical device giant beat Wall Street expectations and increased its full-year earnings guidance.

What You'll Want to Know About Medtronic's Solid Q1 Earnings Results

Shares of Medtronic PLC MDT, +4.28% ran up 4.8% toward a record high in morning trading, to top the S&P 500's SPX, -0.19% list of gainers, after the medical technology company reported second-quarter results that beat expectations and raised its full-year profit outlook.

Medtronic's stock surges to record, paces S&P 500 gainers after upbeat results and outlook

Medtronic (MDT) displays improved performances at CER, banking on growth across all major segmental businesses as well as geographies.

Medtronic (MDT) Beats on Q1 Earnings, Ups FY20 EPS Guidance

Medtronic (NYSE: MDT) reported first-quarter earnings of $1.26 per share, which beat the analyst consensus estimate of $1.18 by 6.78%.

Medtronic Reports Q1 Earnings Beat, Raises Guidance

Medtronic earnings topped Q1 views, with the medical products giant also raising full-year EPS guidance. Medtronic stock rose, signaling a new high.

Medtronic Earnings Top; Medical Products Giant Set To Hit New High

Shares of Medtronic PLC MDT, +1.38% surged 3.5% toward a record high in premarket trading Tuesday, after the medical technology company reported fiscal first-quarter profit and revenue that rose above expectations and raised its full-year outlook.

News for Medtronic Stock (MDT)